Prometic reports positive clinical data from its intravenous immunoglobulin (IVIG) pivotal phase 3 trial

May 1, 2018 Frederic Dumais
  • Clinical data presented at the Clinical Immunology Society Annual Meeting in Toronto, Canada on April 27-28, 2018

  • Pivotal clinical trial meets primary and secondary endpoints

  • Clinical data demonstrates comparable efficacy to commercially-approved drugs

  • Prometic IVIG’s safety and tolerability profiles maintained without any significant drug related issues

Positive Results from IVG Phase 3 Trial

LAVAL, QUEBEC, CANADA – April 30, 2018 – Prometic Life Sciences Inc. (TSX: PLI)

(OTCQX: PFSCF) (Prometic) today announced positive clinical data from its pivotal IVIG phase

3 clinical trial, meeting its clinical primary and secondary endpoints in adult patients suffering from

primary immunodeficiencies (PID). The clinical data presented at the Clinical immunology Society

Annual Meeting in Toronto on April 27-28 2018 on Prometic’s IVIG demonstrated comparable

safety and efficacy data to existing commercial IVIG products without any significant drug related

safety issues.

Primary End Point

The primary end point is the rate of clinically documented serious bacterial infections (SBIs),

defined as bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis,

bacterial meningitis or visceral abscess. The FDA Guidance for Industry on studies required to

support marketing of IGIV states: “…a statistical demonstration of a serious infection rate per

person-year less than 1.0 is adequate to provide substantial evidence of efficacy”. Since there

were no SBIs observed during the study, Prometic IGIV 10% clearly meets this requirement.

Secondary Endpoints

Secondary endpoints including episodes of fever (≥100.4°F), number of missed days, number of

days of hospitalization due to infection, number of days on antibiotics, number of infections other

than SBI, and trough IgG level were comparable between Prometic’s IGIV and commercial drugs.

Only 4.94 days/subject/year were lost from work with Prometic IGIV 10%, which was significantly

less than the rate observed while on commercial product.

The proportion of infusions for which at least one treatment-emergent adverse events (TAAE) that

was reported was well within FDA guidance threshold across all time points within 72-hours postinfusion. Overall Prometic IGIV 10% appeared to be well tolerated and was not associated with

any SBIs.

The Results

“The results with Prometic IGIV 10% met the FDA Guideline requirements for both safety and

efficacy. This is the second plasma derived therapeutic clinical program to generate positive

pivotal phase 3 results” said Pierre Laurin, President and CEO of Prometic. “This demonstrates

the ability of our PPPSTM platform to generate positive data from both rare proteins targeting rare

diseases as well as more commodity like proteins”.

 

The poster presented at the Clinical Immunology Society Annual Meeting in Toronto is available

on Prometic’s corporate website.

What is Intravenous Immunoglobulin?

Intravenous immunoglobulin is a preparation of antibodies purified from plasma donations from

healthy individuals. It is indicated for the maintenance treatment of patients with primary

immunodeficiencies (PID), including common variable immunodeficiency, X-linked

agammaglobulinemia and severe combined immunodeficiency. It is also indicated for the

treatment of immune thrombocytopenic purpura (ITP) and for many other autoimmune diseases,

including Guillain-Barré syndrome, Kawasaki disease.

 

According to recent market data, Canada is ranked as the second country in the world after the

United States for the average consumption of IVIG (measured in kilograms per million people),

with sales exceeding $600 million in 2016. The global IVIG market CAGR is expected to reach

5-6% between 2016 and 2025 with Canada having one of the lowest IVIG self-sufficiency ratios

(i.e. less than 20%).

About Prometic

Prometic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical corporation with two drug

discovery platforms focusing on unmet medical needs in the field of fibrosis and orphan diseases.

The first platform, small molecule therapeutics, stems from the discovery of two receptors

GPR40/GPR84 acting as “dual master switches” which are at the core of the healing process as

opposed to fibrosis. The second platform, plasma-derived therapeutics, leverages Prometic’s vast

experience in bioseparation technologies to address unmet medical needs with therapeutic

proteins not currently commercially available, such as Ryplazim™ (plasminogen human).

 

Prometic is also leveraging the second platform higher recovery yield advantage to develop some

more established plasma-derived therapeutics with significant growth in demand such as

Intravenous Immunoglobulin (IVIG) and provides access to its proprietary bioseparation

technologies to enable pharmaceutical companies in their production of non-competing

biopharmaceuticals. Globally recognized as a bioseparations expert, the Corporation derives

 

revenue from this activity through sales of affinity chromatography media which contributes to

offset the costs of its own R&D investments. Headquartered in Laval (Canada), Prometic has

R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial

activities in the U.S., Canada, Europe and Asia.

 

This press release contains forward-looking statements about Prometic’s objectives, strategies

and businesses that involve risks and uncertainties. These statements are “forward-looking”

because they are based on our current expectations about the markets we operate in and on

various estimates and assumptions. Actual events or results may differ materially from those

anticipated in these forward-looking statements if known or unknown risks affect our business, or

if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include,

but are not limited to, Prometic’s ability to develop, manufacture, and successfully commercialize

value-added pharmaceutical products, the availability of funds and resources to pursue R&D

projects, the successful and timely completion of clinical studies, the ability of Prometic to take

advantage of business opportunities in the pharmaceutical industry, uncertainties related to the

regulatory process and general changes in economic conditions. You will find a more detailed

assessment of the risks that could cause actual events or results to materially differ from our

current expectations in Prometic’s Annual Information Form for the year ended December 31,

2017, under the heading “Risk and Uncertainties related to Prometic’s business”. As a result, we

cannot guarantee that any forward-looking statement will materialize. We assume no obligation

to update any forward-looking statement even if new information becomes available, as a result

of future events or for any other reason, unless required by applicable securities laws and

regulations. All amounts are in Canadian dollars unless indicated otherwise.

 

For further information please contact:

 

Pierre Laurin

President and CEO

Prometic Life Sciences Inc.

p.laurin@prometic.com

450.781.0115

 

Frederic Dumais

Senior Director, Communications & Investor Relations

Prometic Life Sciences Inc.

f.dumais@prometic.com

450-781-0115

 

Bob Yedid

LifeSci Advisors

bob@lifesciadvisors.com

646-597-6989

 

Matt Middleman, M.D.

LifeSci Public Relations

matt@lifescipublicrelations.com

646-627-8384

Previous Article
Prometic reports on its 2018 annual and special meeting of shareholders highlights
Prometic reports on its 2018 annual and special meeting of shareholders highlights

Next Article
Prometic presents new PBI-4050 clinical data from ongoing Alström Syndrome phase 2 trial
Prometic presents new PBI-4050 clinical data from ongoing Alström Syndrome phase 2 trial